About

Products

Pipeline

Research and Development

Regenerative medicine

Pre-clinical and clinical trials

Manufacturing & QA

Partners

Work for us

Contact us

News

Elizaria®

All products

INN: Eculizumab

A humanized monoclonal antibody that binds to the human complement protein C5 and inhibits the activation of complement-mediated cytolysis.

Elizaria® inhibits the activation of the terminal complement co
the regulation of complement activity in the blood.

Elizaria® prevents intravascular hemolysis in patients with par
hemoglobinuria (PNH), as well as excessive activation of the te
complex in patients with atypical hemolytic uremic syndrome (

Eculizumab treatment in patients leads to a significant decreas
of thrombosis, dependence on blood transfusion in patients wit
hemoglobinuria, and also significantly improves renal function
hemolytic uremic syndrome.

Indications for use:

- Paroxysmal nocturnal hemoglobinuria (PNH)
- Atypical hemolytic uremic syndrome (aHUS)

GENERIUM is the only company in the world that has develope
biosimilar of Eculizumab.

Main office

10, ent. 2, Testovskaya st., Moscow,
123112, Russia
Tel: +7 495 988-47-94
Generium@Generium.ru

About

Careers

Our products

Coagil-VII®
Octofactor®
Innonafactor®
Diaskintest®
Infibeta®
T-SPOT®.TB
Tigerase®
Elizaria®
Glurazyme®
Revelise®

All rights reserved. Generium 2019

Site development — **AGIMA** Tech support — **Techart**.